G6PD deficiency may lead to severe hyperbilirubinemia, and even result in bilirubin encephalopathy, which can cause neurological sequelae in newborns and even death.
Conditions
Interventions
Study group: All neonates diagnosed with G6PD deficiency by G6PD enzyme testing.:None
Control group: All newborns with normal G6PD enzyme levels.:None
Sponsors
Yuebei People’s Hospital
Eligibility
Sex/Gender
All
Age
No minimum to 1 Years
Inclusion criteria
Inclusion criteria: 1. Newborns born in the Department of Obstetrics at Yuebei People's Hospital with an age of <= 28 days; 2. Simultaneous G6PD enzymatic testing and tandem mass spectrometry-based genetic metabolic disease screening were conducted; 3. Complete and traceable clinical baseline information and two test results were available; 4. Both parents were in good health with no history of severe acute/chronic diseases or confirmed genetic disorders.
Exclusion criteria
Exclusion criteria: 1. Patients with severe lack of clinical data, rendering propensity score calculations impossible; 2. Individuals with severe congenital malformations, biliary atresia; other known inherited metabolic disorders or any critical illnesses that may significantly impact metabolic profiles; history of birth asphyxia; ischemic-hypoxic encephalopathy, cerebral hemorrhage, or critical infections; 3. Mothers with major metabolic diseases or a history of specific drug exposure during pregnancy that may interfere with neonatal metabolic homeostasis.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Amino acid profile, acylcarnitine profile; | — |
Countries
China
Contacts
Public ContactJianwu Qiu
Yuebei People’s Hospital
Outcome results
None listed